Community crystal gazing

Journal name:
Nature Biotechnology
Volume:
34,
Pages:
276–283
Year published:
DOI:
doi:10.1038/nbt.3515
Published online
Corrected online

A selection of individuals from the biotech ecosystem give their views on the challenges facing the sector over the coming years.

At a glance

Figures

  1. 20 years of revenue from public biotech companies.
    Figure 1: 20 years of revenue from public biotech companies.
  2. Biotech R&D spend and annual approvals of biologics.
    Figure 2: Biotech R&D spend and annual approvals of biologics.
  3. Rising drug revenues.
    Figure 3: Rising drug revenues.
  4. Annual totals for amounts raised in financings of private biotech companies.
    Figure 4: Annual totals for amounts raised in financings of private biotech companies.
  5. Biotech IPOs from 1996 to 2015.
    Figure 5: Biotech IPOs from 1996 to 2015.
  6. Number of FDA drug approvals by type/year.
    Figure 6: Number of FDA drug approvals by type/year.
  7. Number of public biotech companies.
    Figure 7: Number of public biotech companies.
  8. Profit/loss for public biotech sector over time.
    Figure 8: Profit/loss for public biotech sector over time.

    Collective profit achieved in 2007.

Change history

Corrected online 31 March 2016
In the version of this article initially published, Stanley Crooke's name was misspelled as “Crook” in the author list. The error has been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

  1. Mapmygenome, Hyderabad, India.

    • Anu Acharya
  2. SV Life Sciences, London, UK.

    • Kate Bingham
  3. Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.

    • Jay Bradner
  4. University of Washington, Seattle, Washington, USA.

    • Wylie Burke
  5. University of Wisconsin, Madison, Wisconsin, USA.

    • R Alta Charo
  6. Amyris, Emeryville, California, USA.

    • Joel Cherry
  7. Cellectis, Paris, France.

    • André Choulika
  8. Yumanity Therapeutics, Cambridge, Massachusetts, USA.

    • Tony Coles
  9. Duke University, Durham, North Carolina, USA.

    • Robert Cook-Deegan
  10. Ionis Pharmaceuticals, Carlsbad, California, USA.

    • Stanley T Crooke
  11. Kaitek Labs, Santiago, Chile.

    • Emilia Díaz
  12. Biotechnology Innovation Organization, Washington, DC, USA.

    • Brent Erickson &
    • James C Greenwood
  13. Information Technology and Innovation Foundation, Washington, DC, USA.

    • L Val Giddings
  14. Organ Preservation Alliance, Ossium and Sylvatica Biotech, New York, New York, USA.

    • Sebastian Eriksson Giwa
  15. Draper Espirit, London, UK.

    • Vishal Gulati
  16. Apple Tree Partners, New York, New York, USA.

    • Sam Hall
  17. University of Manchester, Manchester, UK.

    • John Harris
  18. PatientsLikeMe and AOBiome, Boston, Massachusetts, USA.

    • Jamie Heywood
  19. GNS Healthcare, Cambridge, Massachusetts, USA.

    • Colin Hill
  20. Ovid Therapeutics, New York, New York, USA.

    • Jeremy Levin
  21. Spiral Genetics, Seattle, Washington, USA.

    • Adina Mangubat
  22. Alnylam, Cambridge, Massachusetts, USA.

    • John Maraganore
  23. Medicxi Ventures, Geneva, Switzerland.

    • Giovanni Mariggi
  24. DuPont Pioneer, Wilmington, Delaware, USA.

    • Barbara J Mazur
  25. Baylor College of Medicine, Houston, Texas, USA.

    • Amy L McGuire
  26. EuropaBio, Brussels, Belgium.

    • Nathalie Moll
  27. University of Pennsylvania, Philadelphia, Pennsylvania, USA.

    • Jonathan Moreno
  28. Histogen, San Diego, California, USA.

    • Gail Naughton
  29. Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Lita Nelsen
  30. BioIndustry Association, London, UK.

    • Jane Osbourn
  31. Oxbridge Biotech Roundtable, London, UK.

    • Daniel Perez
  32. Roche, Basel, Switzerland.

    • John Reed
  33. SG Cowan, New York, New York, USA.

    • Eric Schmidt
  34. MyOwnMed, Chevy Chase, Maryland, USA.

    • Vicki Seyfert-Margolis
  35. Johnson & Johnson, New Brunswick, New Jersey, USA.

    • Paul Stoffels
  36. XOventure International, Lucerne, Switzerland.

    • Jørgen Thorball
  37. In-Q-Tel, Arlington, Virginia, USA.

    • Tara O'Toole
  38. Xpressomics, Tallinn, Estonia.

    • Indrek Vainu
  39. Forbion Capital Partners, Naarden, The Netherlands.

    • Sander van Deventer
  40. Sanofi, Paris, France.

    • Elias Zerhouni
  41. PureTech Health, Cambridge, Massachusetts, USA.

    • Daphne Zohar

Author details

Supplementary information

PDF files

  1. Supplementary Tables (186 KB)

    Supplementary Tables 1–4

Additional data